Cite
HARVARD Citation
Brannagan, T. et al. (2020). Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial. European journal of neurology. pp. 1374-1381. [Online].